electroCore, Inc. Common Stock
ECOR Real Time Price USDRecent trades of ECOR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ECOR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
ECOR Revenue by Segment or Geography
New patents grants
-
Patent Title: Devices and methods for non-invasive vagal nerve stimulation Jan. 28, 2025
-
Patent Title: Devices and methods for non-invasive nerve stimulation Dec. 31, 2024
-
Patent Title: Systems and methods for initial provisioning and refilling of medical devices Dec. 24, 2024
-
Patent Title: Non-invasive electrical stimulation for medical disorders Dec. 24, 2024
-
Patent Title: Systems and methods for treating a medical condition Dec. 17, 2024
-
Patent Title: Devices and methods for treating or preventing development disorders Dec. 17, 2024
-
Patent Title: Vagal nerve stimulation for treating dopamine-related conditions Aug. 27, 2024
-
Patent Title: Devices and methods for determining the effectiveness of electrical stimulation Aug. 06, 2024
-
Patent Title: Non-invasive nerve stimulation with mobile device Apr. 02, 2024
-
Patent Title: Vagal nerve stimulation for treating central nervous system disorders Apr. 02, 2024
-
Patent Title: Vagal nerve stimulation for treating post-traumatic stress disorder Jan. 09, 2024
-
Patent Title: Medical devices for treating medical conditions Dec. 26, 2023
-
Patent Title: Devices and methods for remote therapy and patient monitoring Dec. 26, 2023
-
Patent Title: Systems and methods for treating a medical condition with an electrical stimulation treatment regimen Dec. 12, 2023
-
Patent Title: Systems and methods for vagal nerve stimulation Oct. 10, 2023
-
Patent Title: Nerve stimulator for use with a mobile device Sep. 26, 2023
-
Patent Title: Non-invasive nerve stimulation with mobile device Jul. 18, 2023
-
Patent Title: Systems and methods for initial provisioning and refilling of medical devices Jun. 27, 2023
-
Patent Title: Stimulator for use with a mobile device Jun. 20, 2023
-
Patent Title: Nerve stimulation devices and methods May. 23, 2023
-
Patent Title: Vagal nerve stimulation for treating dopamine-related conditions Apr. 11, 2023
-
Patent Title: Vagal nerve stimulation devices and methods for treating medical conditions Apr. 11, 2023
-
Patent Title: Devices and methods for non-invasive vagal nerve stimulation Apr. 11, 2023
-
Patent Title: Vagal nerve stimulation therapy Feb. 28, 2023
-
Patent Title: Technologies for initial provisioning and refilling of medical devices Feb. 14, 2023
-
Patent Title: Non-invasive nerve stimulation to treat or prevent autism spectrum disorders and other disorders of psychological development Dec. 27, 2022
-
Patent Title: Non-invasive vagal nerve stimulation to treat disorders Dec. 06, 2022
-
Patent Title: Non-invasive magnetic or electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders Nov. 29, 2022
-
Patent Title: Non-invasive nerve stimulation to patients Oct. 04, 2022
-
Patent Title: Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders Oct. 04, 2022
-
Patent Title: Stimulator for use with a mobile device Sep. 20, 2022
-
Patent Title: Electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders Sep. 13, 2022
-
Patent Title: Devices and methods for remote therapy and patient monitoring Sep. 06, 2022
-
Patent Title: Mobile phone for treating a patient with dementia Aug. 09, 2022
-
Patent Title: Devices and methods for electrical stimulation and their use for vagus nerve stimulation on the neck of a patient Aug. 02, 2022
-
Patent Title: Systems and methods for treating headache with vagal nerve stimulation Jul. 19, 2022
-
Patent Title: Devices and methods for monitoring non-invasive vagus nerve stimulation Jul. 19, 2022
-
Patent Title: Nerve stimulation devices and methods for treating cardiac arrhythmias Jun. 07, 2022
-
Patent Title: Devices and methods for vagal nerve stimulation May. 10, 2022
-
Patent Title: Non-invasive vagus nerve stimulation Apr. 12, 2022
-
Patent Title: Methods and devices for treating primary headache Apr. 05, 2022
-
Patent Title: Nerve stimulator for use with a mobile device Mar. 01, 2022
-
Patent Title: Mobile phone for treating a patient with seizures Jan. 25, 2022
-
Patent Title: Medical self-treatment using non-invasive vagus nerve stimulation Dec. 14, 2021
-
Patent Title: Systems and methods for vagal nerve stimulation Dec. 07, 2021
-
Patent Title: Non-invasive vagus nerve stimulation devices and methods to treat or avert atrial fibrillation Nov. 23, 2021
-
Patent Title: Devices and methods for nerve stimulation Oct. 19, 2021
-
Patent Title: Devices and methods for nerve stimulation Oct. 12, 2021
-
Patent Title: Devices and methods for nerve stimulation Sep. 21, 2021
-
Patent Title: Mobile phone using non-invasive nerve stimulation Aug. 24, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ECOR
Recent picks made for ECOR stock on CNBC
ETFs with the largest estimated holdings in ECOR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ECOR stock a Buy, Sell, or Hold?
- What is the price target for $ECOR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ECOR stock?
- Who owns the most shares of $ECOR stock?
- What funds own $ECOR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ECOR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.